Clinical Partnerships Excision BioTherapeutics is a clinical stage CRISPR focused biotech actively advancing HBV and HIV programs and has a collaboration with Temple University, indicating a readiness to engage external development partners for preclinical translational and early clinical work.

Manufacturing Needs As a small company pushing into clinical development, Excision will require specialized GMP manufacturing, vector production, and process development support; this presents opportunities for CDMOs and analytical testing partners to provide scalable manufacturing, release testing, and QA systems.

Data Security The tech stack relies on AWS, Cloudflare, and secure web practices, signaling a strong emphasis on data security and cloud based data management; opportunities exist for cloud hosting, bioinformatics, data integration, and regulatory compliant analytics services tailored to clinical gene therapy programs.

Funding Alliances With revenue in the low to mid single digits and recognition as a Fierce 15 innovator, Excision may pursue strategic investments, co development deals, or grant supported programs to accelerate clinical milestones, creating sales opportunities in funding advisory, regulatory consulting, and strategic partnerships.

Market Visibility Regular participation in industry events (ICE-HBV, ASGCT) and press coverage suggests openness to collaboration and licensing discussions; BD efforts could focus on establishing inbound interest for research collaborations, licensing negotiations for HBV and HIV assets, and joint development discussions.